Raloxifene manifests itself as estrogen agonistic-like effects in the bone and cardiovascular system, estrogen antagonism-like effects in the uterus and mammary glands, and can be used to prevent and treat osteoporosis in postmenopausal women, improve menopausal symptoms in postmenopausal women, and has potential cardiovascular protective effects. Raloxifene is a selective estrogen receptor modulator that binds to estrogen receptors and activates certain estrogen pathways while blocking others. Raloxifene reduces bone resorption and reduces biochemical markers of bone turnover to the premenopausal range. Reduces the incidence of vertebral fractures, preserves bone mass and increases bone density. It can also affect lipid metabolism, reduce total cholesterol and LDL cholesterol levels, but do not increase triglyceride levels, and have no effect on overall HDL levels.
Raloxifene is a selective estrogen receptor modulator for postmenopausal osteoporosis.
|Appearance||Yellowish powder||Yellowish powder|
|Loss on drying||≤0.5%||0.12%|
|Residue on ignition||≤0.1%||0.08%|
|Total related compounds||≤0.5%||0.35%|
|Assay(on dried basis)||≥105%||107.6%|
|Package details:||50g/bottle; 100g/foil bag; 200g/foil bag|
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!